Los Angeles, CA -- (SBWIRE) -- 01/30/2019 -- In the recently published report, QY Research has provided a unique insight into the global Irritable Bowel Syndrome market for the forecasted period of 7-years (2018-2025). The report has covered the significant aspects that are contributing to the growth of the global Irritable Bowel Syndrome market. The primary objective of this report is to highlight the various key market dynamics such as drivers, trends, and restraints that are impacting the global Irritable Bowel Syndrome market. This report has provided an indication to the readers about Irritable Bowel Syndrome market's current status.
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.
Get PDF report template at https://www.qyresearch.com/sample-form/form/948402/global-irritable-bowel-syndrome-ibs-forecast-amp%3B-opportunities
The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.
The global Irritable Bowel Syndrome (IBS) market is valued at 2640 million US$ in 2018 is expected to reach 8650 million US$ by the end of 2025, growing at a CAGR of 16.0% during 2019-2025.
This report focuses on Irritable Bowel Syndrome (IBS) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome (IBS) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, and Japan.
At the company level, this report focuses on the production capacity, ex-factory price, revenue, and market share for each manufacturer covered in this report.
The following manufacturers are covered:
Allergan
Valeant Pharmaceuticals
Takeda
Sucampo Pharmaceuticals
McNeil Consumer Healthcare
Sebela Pharmaceuticals
Astellas Pharmaceuticals
IM HealthScience
Segment by Regions
North America
Europe
China
Japan
Segment by Type
IBS-D Drug
IBS-C Drug
Other
Segment by Application
Women
Men
Get Complete Report in your Inbox within 24 hours at https://www.qyresearch.com/index/detail/948402/global-irritable-bowel-syndrome-ibs-forecast-amp%3B-opportunities
About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.